Abstract
The drug gefitinib (Iressa), which is a specific inhibitor of EGFR tyrosine kinase, has been shown to suppress the activation of EGFR signaling for survival and proliferation in non-small cell lung cancer (NSCLC) cell lines. A recent study demonstrated rapid down-regulation of ligand-induced EGFR in a gefitinib-sensitive cell line and inefficient down-regulation of EGFR in a gefitinib-resistant cell line in the exponential phase of growth; this implies that each cell type employs a different unknown down-regulation mechanism occurs. However, the mechanism of drug sensitivity to gefitinib remains unclear. In this study, to further substantiate the effect of gefitinib on the EGFR down-regulation pathway and to understand the detailed internalization mechanism of gefitinib-sensitive PC9 and gefitinib-resistant QG56 cell lines, we examined the internalization of Texas red-EGF in the absence or presence of gefitinib in both cell lines. The distribution of internalized Texas red-EGF, early endosomes, and late endosomes/lysosomes was then assessed by confocal immunofluorescence microscopy. Here, we provide novel evidence that efficient endocytosis of EGF–EGFR occurs via the endocytic pathway in the PC9 cells, because the internalized Texas red-EGF-positive small punctate vesicles were transported to the late endosomes/lysosomes and then degraded within the lysosomes after 60 min of internalization. Additionally, gefitinib exerted a strong inhibitory effect on the endocytosis of EGFR in PC9 cells, and the internalization rate of EGFR from the plasma membrane via the early endosomes to the late endosomes/lysosomes was considerably delayed. This indicates that gefitinib efficiently suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in PC9 cells. In contrast, the internalization rate of ligand-induced EGFR was not significantly changed by gefitinib in QG56 cells because even in the absence of gefitinib, internalized EGFR accumulation was noted in the early and late endosomes after 60 min of internalization instead of its delivery to the lysosomes in QG56 cells. This suggests that the endocytic machinery of EGFR might be basically impaired at the level of the early/late endosomes. Taken together, this is the first report demonstrating that the suppressive effect of gefitinib on the endocytosis of EGFR is much stronger with PC9 cells than QG56 cells. Thus, impairment in some steps of the EGF–EGFR traffic out of early endosomes toward the late endosomes/lysosomes might confer gefitinib-resistance in NSCLC cell lines.
Similar content being viewed by others
References
Arteaga CL, Johnson DH (2001) Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13:491–498
Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P (1998) Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 393:805–809
Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911–1914
Baselga J, Averbuch SD (2000) ZD1839 (‘Iressa’) as an anticancer agent. Drugs 60(Suppl1):33–40; discussion 41–42
Bock JB, Klumperman J, Davanger S, Scheller RH (1997) Syntaxin 6 functions in trans-Golgi network vesicle trafficking. Mol Biol Cell 8:1261–1271
de Bono JS, Rowinsky EK (2002) The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 8:19–26
Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotton M, Kéri G, Wissing J, Daub H (2005) Cellular targets of gefitinib. Cancer Res 65:379–382
Hirata A, Uehara H, Izumi K, Naito S, Kuwano M, Ono M (2004) Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib (‘Iressa’, ZD1839). Cancer Sci 95:614–618
Kornfeld S, Mellman I (1989) The biogenesis of lysosomes. Ann Rev Cell Biol 5:483–525
Kroemer G, Jäättelä M (2005) Lysosomes and autophagy in cell death control. Nature Rev Cancer 5:886–897
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Eng J Med 350:2129–2139
Mendelsohn J, Baserga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550–6565
Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzyme in cancer. Nature Rev Cancer 6:764–775
Nishimura Y, Higaki M, Kato K (1987) Identification of a precursor form of cathepsin D in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Biochem Biophys Res Commun 148:335–343
Nishimura Y, Kawabata T, Kato K (1988) Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 261:64–71
Nishimura Y, Sameni M, Sloane BF (1998) Malignant transformation alters intracellular trafficking of lysosomal cathepsin D in human breast epithelial cells. Pathol Oncol Res 4:283–296
Nishimura Y, Itoh K, Yoshioka K, Uehata M, Himeno M (2000) Small guanosine triphosphatase Rho/Rho-associated kinase as a novel regulator of intracellular redistribution of lysosomes in invasive tumor cells. Cell Tissue Res 342:341–351
Nishimura Y, Itoh K, Yoshioka K, Ikeda K, Himeno M (2002) A role for small GTPase RhoA in regulating intracellular membrane traffic of lysosomes in invasive rat hepatoma cells. The Histochem J 34:189–213
Nishimura Y, Itoh K, Yoshioka K, Tokuda K, Himeno M (2003) Overexpression of ROCK in human breast cancer cells. Evidence that ROCK activity mediates intracellular membrane traffic of lysosomes. Pathol Oncol Res 9:83–95
Nishimura Y, Yoshioka K, Bernard O, Himeno M, Itoh K (2004) LIM kinase 1: evidence for a role in the regulation of intracellular vesicle trafficking of lysosomes and endosomes in human breast cancer cells. Eur J Cell Biol 34:189–213
Nishimura Y, Yoshioka K, Bernard O, Bereczky B, Itoh K (2006) A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem Cell Biol 126:627–638
Okazaki I, Himeno M, Ezaki J, Ishikawa T, Kato K (1992) Purification and characterization of an 85 kDa sialoglycoprotein in rat liver. J Biochem 111:763–769
Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M (2004) Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the EGF receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3:465–472
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Sandoval IV, Arredondo JJ, Alcalde J, Gonzalez-Noriega A, Vandekerckhove J, Jimenez MA, Rico M (1994) The residues Leu (Ile) 475-Ile (Leu) 476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMPII to lysosomes. J Biol Chem 269:6622–6631
Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306:1506–1507
Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885–4892
Tabuchi N, Akasaki K, Tsuji H (2000) Two acidic amino acid residues, Asp (470) and Glu (471), contained in the carboxyl cytoplasmic tail of a major lysosomal membrane protein, LGP85/LIMPII, are important for its accumulation in secondary lysosomes. Biochem Biophys Res Commun 270:557–563
Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212
Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250
Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K (1998) Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 393:809–812
Yarden Y (2001) The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 37:3–8
Zhang L, Gjoerup O, Roberts TM (2004) The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci USA 101:10296–10301
Author information
Authors and Affiliations
Corresponding author
Additional information
Iressa is a trademark of the AstraZeneca group of companies.
Rights and permissions
About this article
Cite this article
Nishimura, Y., Bereczky, B. & Ono, M. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol 127, 541–553 (2007). https://doi.org/10.1007/s00418-007-0281-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-007-0281-y